BNT166a
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mpox (Monkeypox)
Conditions
Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection
Trial Timeline
Feb 20, 2026 → Jun 1, 2027
NCT ID
NCT07379580About BNT166a
BNT166a is a phase 2 stage product being developed by BioNTech for Mpox (Monkeypox). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07379580. Target conditions include Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection.
What happened to similar drugs?
0 of 2 similar drugs in Mpox (Monkeypox) were approved
Approved (0) Terminated (1) Active (1)
❌Tecovirimat Oral Capsule + Placebo for Tecovirimat + Tecovirimat Oral Capsule (Open Label)SIGA TechnologiesPhase 3
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07379580 | Phase 2 | Recruiting |
| NCT05988203 | Phase 1/2 | Active |
Competing Products
5 competing products in Mpox (Monkeypox)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1769 | Moderna | Phase 2 | 0 |
| MVA-BN | Bavarian Nordic | Phase 2 | 36 |
| MVA-BN standard regimen + MVA-BN half-dose regimen | Bavarian Nordic | Phase 3 | 44 |
| Jynneos + MVA-BN (Quail) | Bavarian Nordic | Phase 2 | 39 |
| Tecovirimat Oral Capsule + Placebo for Tecovirimat + Tecovirimat Oral Capsule (Open Label) | SIGA Technologies | Phase 3 | 22 |